XtalPi and ReviR Therapeutics push AI-designed RTX-117 into human trials for rare neurological disorders
RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.